DENVER, Dec. 14, 2010 (GLOBE NEWSWIRE) -- MusclePharm® Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States, announced today that it will begin a clinical research program with the Metabolic and Body Composition Laboratory in the department of Health and Exercise Science at the University of Oklahoma to determine the effects of MusclePharm Assault® beginning in January 2011.
The clinical research program will be led by Jeffrey R. Stout, Ph.D, MusclePharm's Scientific Advisor, who is an Associate Professor and Director of the OU lab. Stout, along with other faculty in the department, will study the effects of MusclePharm's products on high-intensity interval training, on aerobic and anaerobic power, repeated sprint ability, body composition, training volume and strength levels.
MusclePharm Assault® is rated as a top pre-workout supplement on numerous, premier websites. Scoring 9.2 out of 10 on bodybuilding.com proves Assault® to be at the top of its category. With previous assessments and reviews performed by thousands of satisfied customers in conjunction with the research team at the University of Oklahoma, MusclePharm is once again proving themselves as an industry leader.
"We are excited to be working with the University of Oklahoma and such an esteemed team focused on health and exercise science to further understand the results of MusclePharm Assault®," commented, Brad Pyatt, MusclePharm's Chief Executive Officer. "As one of the leading developers and manufacturers of nutritional supplements we continue to focus on safe and scientific product formulations that will benefit the global healthy living and wellness industry as we strive to increase sales and profitability long-term."
The research team at the University of Oklahoma has conducted and published numerous studies that focus on nutritional interventions on exercise performance, muscle function and body composition, fueling excitement for MusclePharm and the future potential for the product line.
Headquartered in Denver, Colorado, MusclePharm is a rapidly expanding healthy life-style company that develops and manufacturers a full line of NSF and scientifically approved nutritional supplements that are 100% free of any banned substances. Based on years of research, MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than 100 elite professional athletes from various sports including the NFL, MMA, and MLB. The Company's propriety and award winning products address all categories of an active lifestyle including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen. MusclePharm is sold in over 120 countries and available in over 5,000 U.S. retail outlets that include GNC, and Vitamin Shoppe, as well as over 100 online stores, including bodybuilding.com, Amazon and Vitacost.com. For more information, please visit .
MusclePharm Corporation believes the information set forth in this Press Release may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in "Risk Factors" in Item 2.02 of the Company's Form 8-K dated February 18, 2010, which has been filed with the Securities and Exchange Commission.
CONTACT: ICR Investor Contact: John Mills, Senior Managing Director 310.954.1105